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Aims. Oncocytic (Hurthle) follicular cell tumors (OTs) of the thyroid are both adenomas (OAs) and follicular carcinomas (OCs).
The routine diagnosis of these tumors can be problematic even after an accurate sampling and histological examination. Beside
preoperative evaluation due to the tumor’s dimension several studies have been performed to find markers able to distinguish
malignant from benign follicular tumors in the thyroid, with Galectin-3 being one of the most effective. Recently, some authors
suggested cyclin D3 as adjunct to the diagnosis of the oncocytic lesions of the thyroid.Methods and Results. In this paper we assess
the role of Galectin-3 and cyclin D3 in a well-selected group of follicular oncocytic tumors (14OCs and 26OAs). The diameter of
each lesion was also evaluated. The combination of Galectin-3 and cyclin D3 has a good specificity (81%) and sensitivity (100%).
Moreover, the maximum diameter (in cm) of OCs is greater than OAs (4.1 versus 2.3). Conclusions. We believe that the use of
Galectin-3 and cyclin D3 in OTs of the thyroid can be a helpful panel in daily practice when histology is doubtful.
This paper is dedicated to the memory of Nicola Pacilio, a great scientist, and an excellent teacher, an example of human
humility, who died in August 2010
1. Introduction
Hurthle cell thyroid tumors (also called oncocytic or ox-
yphilic thyroid tumors) are uncommon thyroid lesions. By
definition, they are composed predominantly of follicular
cells (75% or more) with deeply eosinophilic cytoplasm on
haematoxylin and eosin (H&E) stained sections [1]. In the
past [2], it has been proposed that all Hurthle cell neoplasms
should be regarded as malignant or potentially malignant.
Recently, these tumors have been divided into two cate-
gories: the benign oncocytic adenoma (OA) and itsmalignant
counterpart, follicular oncocytic carcinoma (OC), showing
blood vessel invasion and/or capsular penetration. OC is
an uncommon thyroid malignancy, representing about 2-
3% of all thyroid carcinomas [3]. Some tumors may also
have relatively small cells, high nucleus/cytoplasm ratios, and
solid/trabecular architecture. For such lesions, having one
or more of these features but lacking unequivocal sign of
malignancy, Rosai and Tallini have suggested the following
terms: atypical Hurthle cell adenomas/Hurthle cell tumors of
uncertainmalignant potential (HCT-UMP) [1]. Rosai and the
Chernobyl thyroid group of pathologists recommended, for
tumors showing questionable capsular invasion, the term fol-
licular tumor of uncertain malignant potential (FT-UMP) if
papillary thyroid carcinoma- (PTC-) type nuclear changes are
absent and well differentiated tumor of uncertain malignant
potential (WDT-UMP) in case of questionable (incomplete)
PTC-type nuclear changes [1]. Several attempts have been
made to support the distinction between follicular adenomas
and carcinomas, including the oncocytic type, using clinical
characteristics and immunohistochemistry. Sippel et al. [4]
found an association between tumor dimensions and risk
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of nodal positivity in patients diagnosed with an oncocytic
thyroid tumor by preoperative fine needle aspiration (FNA)
biopsy. Similarly, Erickson et al. [5] showed that the larger the
size of an oncocytic lesion, the higher the risk of malignancy.
Many markers have been used to classify oncocytic neo-
plasms. Among these, Galectin-3 (Gal-3), a 𝛽-galactoside-
binding protein involved in regulating cell-cell and cell-
matrix interactions, is a very promising one and has been
shown to represent a very helpful adjunct to FNA biopsy of
thyroid nodules [6]. Regarding Hurthle cell thyroid lesions,
some authors [7] have demonstrated a very good sensitivity
(95.1%) and specificity (88%) for Gal-3 as a marker for
OCs. Furthermore, in combination with the marker HMBE-
1, they reported an excellent sensitivity for this panel (99%).
However, other papers [8–10] have suggested that Gal-3
immunoreactivity is not restricted to malignant neoplasms
but can also be detected in thyroid adenomas.
Some investigators [5–11] have performed immunohis-
tochemistry studies focusing their attention on proliferative
activity (Ki-67) and found lower activity in OAs compared
to OCs. Moreover, other results [12] have shown that high
proliferative activity is evident only in Hurthle cell carcino-
mas with clinically aggressive behaviour. Recently, studies
have been performed to assess the role and diagnostic value
of D-cyclins as diagnostic markers in cases of oncocytic
thyroid lesions. The cyclin D family plays a pivotal role
in the regulation of G1/S-phase cell transition [13], and
D-cyclins are overexpressed in different types of cancers
[13]. Cyclin D1, for example, was found to be absent in
normal thyroid tissue [12] and was as effective as cyclin
D3 (100% specificity) in determining the behaviour of FNA
specimens suspicious for Hurthle cell neoplasia [14]. Both
of the markers, however, showed a low sensitivity; thus, the
authors conclude that there should be increased suspicion
for malignancy in indeterminate oncocytic lesions of the
thyroid that overexpress cyclin D3. They concluded that
the risk of malignant behaviour increases with the rate of
cyclin D3-expressing cells. Its diagnostic value is improved by
combination with cyclin D1 evaluation.
Troncone et al. [15] demonstrated that, in OCs, the
accumulation of p27 (kip1) is associated with cyclin D3
overexpression, suggesting that cyclin D3 is a helpful marker
when the histology is unclear. The aim of our study was to
evaluate the hypothesis that a combination of tumor diameter
and immunohistochemical expression of cyclin D3 and Gal-
3 is helpful in distinguishing between benign and malignant
thyroid lesions.
2. Material and Methods
We retrieved all cases of thyroid specimens from 1995 to
2007 matching the key words: “Oncocytic OR Oxyphilic OR
Hurthle”. All cases of medullary and papillary carcinomas
(oncocytic variants) were excluded. After registering the
diameter of each specimen in the initial cohort of 96 cases,
we excluded cases of hyperplastic nodules and oncocytic
metaplasia and cases intermingled with poorly differenti-
ated carcinomas. All slides of the remaining 58 cases were
reevaluated by investigator Claudio Cacchi (CC). Only cases
that clearly had capsular and/or vascular invasion (OCs)
and cases that clearly did not have vascular and/or capsular
invasion (OAs) were chosen for further investigation. We
obtained a final group of 40 cases (14 OCs and 26 OAs).
Formalin-fixed, paraffin-embedded tissue specimens were
available from each case. A representative sample of each
lesion was selected for the successive immunohistochemical
investigation. 3-4𝜇m slides were cut and stained for Gal-
3 (Monoclonal Mouse Anti-Human; Clone 9C4, dilution
1 : 100, Novocastra) and for cyclin D3 (Monoclonal Mouse
Anti-Human; Clone DCS-22, dilution 1 : 40, Novocastra) to
assess the percentage of positive tumor cells. Immunostains
were developed according to an antigen retrieval treatment
(in citrate buffer at pH 6.0) using a biotin-free detection
system (En Vision, DakoCytomation).
Each antibody was tested with external positive and
negative control, and for Gal-3 we also considered foamy
macrophages to be an internal positive control. Both Gal-
3 and cyclin D3 expression were assessed/evaluated by two
independent investigators Claudio Cacchi (CC) and Bruno
Märkl (BM), without knowledge of the clinic pathological
status of the cases. Each slide was scanned at low power
magnification (×1.6 lens) to assess the average percentage
of tumor cells positive for each marker. We considered true
positive cells to be only those that showed nuclear reactivity
for cyclin D3 and concomitant/simultaneous nuclear and
cytoplasmic reactivity for Gal-3. For Gal-3 and cyclin D3,
cutoffs of ≥1% and ≥25% have been chosen to classify cases
as positive [7, 14].
Results from investigator Claudio Cacchi (CC) were used
to evaluate the specificity and sensitivity of each antibody
tested alone or in combination.
This study was performed according to the national rule,
that is, law of hospitals in Bavaria (Bayerisches Krankenhaus-
gesetz). This study has been also examined by the internal
review board.
3. Statistics
For the comparison of the results, the paired 𝑡-test or Mann-
Whitney rank sum test was used, depending on the normality
test. 𝑃 values < 0.05 were considered significant.
The averaged results are shown as mean values ±1 stan-
dard deviation (SD). All calculations were performed using
the Sigma Plot 11.0 software package (Systat, Richmond,
USA).
A kappa value (𝜅) was also calculated to estimate the
interobserver agreement for both immunohistochemical
evaluations; an absolute difference of ≤10% in two measures
was considered agreement.
4. Results
The maximum diameter (in cm) of OCs was greater than in
OAs (4.1 ± 2.3 versus 2 ± 0.8) (𝑃 < 0.001).
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Figure 1: Immunohistochemical features. It should be noted that
also Hashimoto thyroiditis may show reactivity for Galectin-3, but
it is typical focal and restricted to epithelial cells in the areas of
lymphocytic infiltrations. Gal-3 in OC: note the diffuse reaction in
tumor cells (arrowheads).
Figure 2: Immunohistochemical features. It should be noted that
also Hashimoto thyroiditis may show reactivity for Galectin-3, but
it is typical focal and restricted to epithelial cells in the areas of
lymphocytic infiltrations. Gal-3 in OA: compare the negative tumor
with the positive macrophages (top, arrows).
The results of the investigators had good [16] agreement
for both Gal-3 and cyclin D3 (𝜅 = 0.8 and 0.7, resp.).
The mean values of Gal-3 in OCs versus OAs were
(Claudio Cacchi (CC) and Bruno Märkl (BM)) 25% ± 25%
and 24% ± 26% versus 3% ± 8% and 6% ± 17% (Figures 1 and
2). The examiners’ results (Claudio Cacchi (CC) and Bruno
Märkl (BM)) showed a significant difference in percentage (𝑃
value < 0.001 and 0.002) of positive tumor cells between OCs
and OAs.
Figure 3: Immunohistochemical features. It should be noted that
also Hashimoto thyroiditis may show reactivity for Galectin-3, but
it is typical focal and restricted to epithelial cells in the areas of
lymphocytic infiltrations. Immunostaining with cyclin D3 with a
diffuse and strong reaction in OC.
Figure 4: Immunohistochemical features. It should be noted that
also Hashimoto thyroiditis may show reactivity for Galectin-3, but
it is typical focal and restricted to epithelial cells in the areas of
lymphocytic infiltrations. OA: only few cells show a weak positivity
for cyclin D3 (arrows).
The results for cyclin D3 are the following (Claudio
Cacchi (CC) and Bruno Märkl (BM)): 46% ± 37% and
47% ± 33% in OCs and 8% ± 13% and 13% ± 17% in OAs
(Figures 3 and 4). The two evaluations also showed cyclin D3
overexpression in theOCswith respect to theOAs (𝑃 < 0.001
and 𝑃 = 0.001, resp.).
Gal-3 as marker of malignancy showed a relatively good
sensitivity (79%) and specificity (81%). Although the sen-
sitivity of cyclin D3 as a single marker was low (50%), its
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Table 1
Oncocytic carcinomas (14) Oncocytic adenomas (26)
Diameter (cm) 4.11 ± 2.3 2 ± 0.8
Cyclin D3 (Claudio Cacchi (CC)) (% of tumor cells) 46 ± 37 8 ± 13
Cyclin D3 (Bruno Märkl (BM)) (% of tumor cells) 47 ± 33 13 ± 17
Galectin-3 (Claudio Cacchi (CC)) (% of tumor cells) 25 ± 25 8 ± 13
Galectin-3 (Bruno Märkl (BM)) (% of tumor cells) 24 ± 26 13 ± 17
Table 2
Cyclin D3 Galectin-3 Gal-3 OR cyclin D3
Sensitivity 50% 79% 100%
Specificity 96% 81% 81%
specificity was very high (96%). A combination of the two
markers (Gal-3+ OR cyclin D3+) demonstrated excellent
sensitivity (100%) and a quite good specificity (81%). The
results are summarized in Tables 1 and 2.
5. Discussion
For the FT-UMP or the HCT-UMP cases, Papotti et al. [17]
demonstrated that there is no benefit with Gal-3 and HBME-
1 immunoprofiling. Herein we studied only cases with either
certain benignity or certain malignancy.
Regarding tumor dimensions, we described an important
difference in the mean diameter of OCs (4.1 cm) in com-
parison to OAs (2 cm). These findings are similar to data
found in the literature. In fact, Erickson et al. [5] reported
a median diameter of 4.8 cm for OCs and 3.1 cm for OAs.
Furthermore, Sippel et al. [4] demonstrated that OCs are
larger thanOAs (5.0 versus 2.7 cm), supporting the predictive
role of neoplasm’s dimensions in cases of FNA biopsy with
examination of oncocyte cytoplasm. In these cases [4], no
malignancy was found for lesions smaller than 2 cm. In our
study, only two out of fourteen cases (14%) in the OC group
were <2 cm (1.5 and 1.7 cm).
Our results, in agreement with the literature [4, 5], under-
score the importance of clinical information and/or macro-
scopic precision in such lesions. The correlation between
tumor diameter and risk of malignancy of oncocytic tumors
of the thyroid suggests the hypothesis of time-related car-
cinogenesis, in which an oncocytic adenoma represents a
premalignant lesion, and the FT-UMP represents “formae
frustrae” of carcinomas. The results published by Erickson et
al. [5] seem to support this hypothesis, showing a diameter
of 3.7 cm for neoplasms of uncertain malignant behaviour
(UMB), which is larger than adenomas but smaller than
carcinomas.
The use of Galectin-3 as an adjunct to routine diag-
nosis of follicular thyroid neoplasms has been previously
demonstrated [6, 18, 19]. However, other studies have found
reactivity for Gal-3 in adenomas [8–10]. A possible expla-
nation for these discrepancies may be the presence of false
positive reactivity forGal-3 due to biotin dependent detection
systems. For this reason, we used a biotin-free system (En
Vision, DakoCytomation).
Focusing on oncocytic cell tumors of the thyroid, Volante
et al. showed a 94.3% rate of Gal-3 positive carcinomas and
a 12% rate of Gal-3 positive adenomas. In this study, Gal-
3 had a sensitivity of 95.1% and a specificity of 88%, and
if used in combination with HBME-1, the sensitivity was
99%. Interestingly, another study [8] illustrated a significant
difference in immunostaining for Gal-3 between OCs and
OAs (59% versus 7.1%). This diversity of percentage in Gal-
3 immunostaining in our study is similar to the literature;
however, probably due to the relatively small number of
carcinomas in our study, the specificity and sensitivity for
Gal-3 are lower than those previously reported [7].
Factors that affect cell cycle machinery, recently well
elucidated, also have been tested in oncocytic follicular
thyroid lesions.
For example, Müller-Höcker [11] showed a higher reac-
tivity for p53 in oncocytic neoplasms of the thyroid (88%
in OCs and 75% in OAs; eight of seventeen OCs but only
three of twenty OAs with reactivity in more than 10% of
the cells) and showed a higher cell proliferation in OCs
than OAs (Ki-67: 76 and 12 cells per 10/HPF, resp.). Hoos
et al. suggested, on the basis of a higher Ki-67 index in
widely invasive Hurthle cell carcinoma, that this marker may
have a role in the diagnosis of Hurthle cell thyroid tumors.
In 2000 [5], Erickson et al. proposed Ki-67 and cyclin D1
as helpful indicators in distinguishing oncocytic adenomas
from carcinomas.
Recently, a study performed on FNA samples with onco-
cytic features using cyclin D3 and cyclin D1 as predictors of
malignancy illustrated a very good specificity (100%) but low
sensitivity (32 and 79%, resp.). The authors of this study [14]
adopted cutoffs of 6.5% and 7.5% to improve the predictive
value of cyclin D1 and cyclin D3, respectively, and they
recommend combining the two markers to enhance this
capability. Interestingly, Troncone et al. demonstrated that
increased p27 expression in oncocytic follicular carcinoma
is a consequence of cyclin D3 overexpression and suggested
that cyclin D3 was a valid immunohistochemical marker for
distinguishing OCs from OAs in cases of unclear histology.
Although translocation 𝑡(6; 14)(p21.1; 32.3) or amplification
of the cyclin D3 gene is observed in different neoplasms,
the mechanism of the overexpression of cyclin D3 in OCs
is still unclear and further investigation in this direction is
needed.
Our study is the first that combines dimension, a nuclear
marker (cyclin D3), and a nuclear-cytoplasmic marker
(Gal-3) to differentiate oncocytic carcinomas and adenomas.
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Because of the possibility of a focal reaction for Gal-3 in
adenomas and to avoid the risk of using a very low threshold
value, we did not use a cutoff in evaluation of this reaction.
On the other hand, we believe that adopting a cutoff of
25% for cyclin D3 is quite easy to perform and reduces the
interobserver variability in routine practice.
Our results on the cyclin D3 expression in tumor cells are
in accordance with those shown by Troncone et al., with a low
interobserver variability (𝜅 = 0.7).
In conclusion, our study, which was performed in a
well-selected series of follicular oncocytic thyroid tumors,
indicates that the combination of Gal-3 and cyclin D3 has
excellent sensitivity (100%) and a relative good specificity
(81%), it is easy to perform, and it demonstrates a good
interobserver agreement.
Moreover, we believe that this panel also may be a useful
combination in FNA cytology or cytological cell-block mate-
rial, because oncocytic follicular lesions of the thyroid could
represent a diagnostic challenge in the praxis. Moreover, it is
important to improve the management of these patients, in
order to avoid unnecessary operations [20]. Positive results of
this panel in case of histologicalmorphology of adenomamay
indicate performing additional section to exclude a capsular
or vascular invasion.
It also could be of interest to evaluate this same panel in
oncocytic follicular tumors of uncertain malignant potential,
after a proper follow-up, to understand better the behaviour
of these lesions.
Conflict of Interests
The authors have no conflict of interests to declare.
Acknowledgment
The authors are grateful to Jenny Müller for the excellent
technical assistance.
References
[1] J. Rosai and G. Tallini, “Thyroid gland,” in Rosai and Ackerman’s
Surgical Pathology, chapter 9, pp. 516–519, Elsevier, 10th edition,
2011.
[2] M. K.McLeod andN.W.Thompson, “Hürthle cell neoplasms of
the thyroid,” Otolaryngologic Clinics of North America, vol. 23,
no. 3, pp. 441–452, 1990.
[3] R. G. Watson, M. D. Brennan, J. R. Goellner, J. A. Van Heerden,
W. M. McConahey, and W. F. Taylor, “Invasive Hürthle cell
carcinoma of the thyroid: natural history and management,”
Mayo Clinic Proceedings, vol. 59, no. 12, pp. 851–855, 1984.
[4] R. S. Sippel, D. M. Elaraj, E. Khanafshar et al., “Tumor size
predicts malignant potential in Hürthle cell neoplasms of the
thyroid,” World Journal of Surgery, vol. 32, no. 5, pp. 702–707,
2008.
[5] L. A. Erickson, L. Jin, J. R. Goellner et al., “Pathologic features,
proliferative activity, and cyclin D1 expression in Hurthle cell
neoplasms of the thyroid,”Modern Pathology, vol. 13, no. 2, pp.
186–192, 2000.
[6] A. Bartolazzi, A. Gasbarri, M. Papotti et al., “Application
of an immunodiagnostic method for improving preoperative
diagnosis of nodular thyroid lesions,” The Lancet, vol. 357, no.
9269, pp. 1644–1650, 2001.
[7] M. Volante, F. Bozzalla-Cassione, R. DePompa et al., “Galectin-
3 and HBME-1 expression in oncocytic cell tumors of the
thyroid,” Virchows Archiv, vol. 445, no. 2, pp. 183–188, 2004.
[8] L. Martins, S. E. Matsuo, K. N. Ebina, M. A. V. Kulcsar, C.
U. M. Friguglietti, and E. T. Kimura, “Galectin-3 messenger
ribonucleic acid and protein are expressed in benign thyroid
tumors,” Journal of Clinical Endocrinology and Metabolism, vol.
87, no. 10, pp. 4806–4810, 2002.
[9] M. C. P. A. Nascimento, H. Bisi, V. A. F. Alves, A. Longatto-
Filho, C. T. Kanamura, and G. Medeiros-Neto, “Differential
reactivity for galectin-3 in Hürthle cell adenomas and carcino-
mas,” Endocrine Pathology, vol. 12, no. 3, pp. 275–279, 2001.
[10] M. Niedziela, J. Maceluch, and E. Korman, “Galectin-3 is
not an universal marker of malignancy in thyroid nodular
disease in children and adolescents,” The Journal of Clinical
Endocrinology &Metabolism, vol. 87, no. 9, pp. 4411–4415, 2002.
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